AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027

Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.